Gianella, SaraRedd, Andrew D.Grabowski, Mary K.Tobian, Aaron A. R.Serwadda, DavidNewell, KevinPatel, Eshan U.Kalibbala, SarahSsebbowa, PaschalGray, Ronald H.Quinn, Thomas C.Reynolds, Steven J.2022-01-202022-01-202015Gianella, S., Redd, A. D., Grabowski, M. K., Tobian, A. A., Serwadda, D., Newell, K., ... & Reynolds, S. J. (2015). Vaginal cytomegalovirus shedding before and after initiation of antiretroviral therapy in Rakai, Uganda. The Journal of infectious diseases, 212(6), 899-903. DOI: 10.1093/infdis/jiv13510.1093/infdis/jiv135https://nru.uncst.go.ug/xmlui/handle/123456789/1369Vaginal shedding of cytomegalovirus (CMV) DNA was determined longitudinally among 96 women coinfected with human immunodeficiency virus (HIV), herpes simplex virus 2, and CMV starting antiretroviral therapy (ART) during a placebo-controlled trial of HSV-2 suppression with acyclovir in Rakai, Uganda. Vaginal CMV was detected in 75 of 96 women (78.0%) and 379 of 1080 individual visits (35.1%). ART status, higher HIV RNAviral load before ART initiation, and younger age were significantly associated with increased frequency of CMV shedding (P < .01). Compared to pre- ART, CMV shedding peaked from month 2 to month 4 after ART initiation, suggesting possible immune reconstitution inflammatory syndrome. Further studies need to determine the clinical significance of asymptomatic CMV shedding.enAcyclovirAntiretroviral therapy (ART)Cytomegalovirus (CMV)Human immunodeficiency virus (HIV)Immune reconstitution inflammatory syndrome (IRIS)ReactivationUgandaArticle